Inoviv
Inoviv delivers custom, multiplexed LC-MS proteomics panels with absolute quantification and end-to-end support for biomarker discovery and validation. These workflows yield high reproducibility and accuracy—helping pharmaceutical teams accelerate development and reduce risk in clinical programs.
Founders
Michael Dove
CEO
Michael graduated from the University of Leeds. He began his career in consulting with Accenture in their Life Sciences division. He is specialized in life sciences technology deployment and worked with some of the largest pharmaceutical companies in the world on R&D.
Ernestas Sirka
Cofounder
Ernestas holds a First Class Honors Master’s in Molecular and Cellular Biology from the University of Bath. He spent time working for Pfizer on formulation research, before becoming a researcher in translational biomarkers at University College London.